Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AUPH - USE STOCKTWITS APP TOO, EVERYONE HOLD YOUR SHARES..THE RESISTANCE IS AT 3.92! LET IT EITHER RUN OR CONSOLIDATE. BUT DON'T SELL!
bad day to be sick :(
missed all market action today!
rules are rules, you post only on AUPH, wanna talk about other stocks, go to a board that allows such.
Either way, fact is, we got played and people are simply selling on stupidity and fear, but no matter, money should be in my account tomorrow (trading account) should be able to add some if any further dips occur.
such a sad pathetic market that it's easily manipulated by media. Rather than just simply going to the main results page and deriving a conclusion on your own.
sheep will always be sheep.
Keekee i appreciate you sharing your life story with us
However, please mentioning other stocks on this board, its only AUPH here.
233 million in volume what a monster
Guys anything you would like to give me to post up, let me know I'll review and post !
let's keep everyone's attention on this
interesting view, explain this further, actually i encourage others to voice their concerns here, I honestly think this stock actually has huge potential, so we should clear the air before we go nuts with price estimates
lmfao, this is the news?
Oh God, im kissing my 500$ good bye!
the real solution for cancer ;) you do realize that CBD (from your green erb) already has been researched into specifically for tumor cells- where it does push the cancerous cells to commit suicide - meaning kill off cancer cells.
but common sense and facts dictate that chemo therapy has a hold of the market right now and it's not planning to let go anytime soon ;)
not for the green erb not for "REVE Tech"
LOL
I'm gonna set my shares to sell at 0.0005 ;) maybe someone will be stupid enough to scoop em.
anyone wants to point me to the "huge news"
bssp ask 84461897 million shares at 0.0001
that's 8.5 k
i don't see this moving until idiots stop selling and idiots start buying
i locked in 5 million shares :P
lets see where this shitty stock goes
if it hits 1 cent a share...im buying the next 10 replies a kfc meal =p lmfao
50k
common assholes - lets bring this stock up ! i wanna pay for my tuition !
where? what?
lol what's so big about this...it's got 166 million in volume ? wtf ?
naw, can't justify it
i was in at .0047 and i sold.
i should live with my mistakes, the facts are there, its chances of hitting higher value are high buttt - i can't not my style
sorry guys! :) rock on!
mannnn monday's earnings?
ughhhh
guys why??
and the volume 57 million
ughhhhhhhh
fine
im putting in 500.
but i need a dip!
somebody sell me some cheepies
never reenter a position out of regret.
;) never date an ex.
good reason why you left. even if you're wrong. u got pride ;)
plenty of fish in the sea
Supply and Demand - Take down any order guys!
stop selling your shares - this is not a short term runner its a long term runner, and we can shorten the amount of time to get to its potential !
why surprised ?
they are trying to get in for cheap ...
I hope it goes a little more lower...
If this hits 1.98 I'm dumping $2k @ 2/share
Currently holding 521 @ 2.3
If so, I'll have 1521@ 2.1 avrg
3.2k investment
Sell at 8.10$/share
=12,320
9,190 profit - worse case by October
A month and 2 weeks to make 9k
Yah
Whoever sold
This msg alone come October, is a BIG F YOU ;)
THE NORTH HAS SPOKEN!
$AUPH Price Target Raised to $10 at H.C. Wainwright
AUPH
$$AUPH$$ NOT A PUMP AND DUMP, THIS HAS BEEN VALUED AT 7$ IT'S A NASDAQ STOCK.
BS PR to collect shares brought it down - the results were great - please review and bring your followers on board !
this needs the right attention for it to get back to its value !
if not more.
$AUPH$ ASAP BIG RUN!!!
http://investorshub.advfn.com/Aurinia-Pharmaceuticals-Inc-AUPH-17672/
CHECK IT OUT! GET OTHERS TO CHECK IT OUT
AUPH
Ok for all you non-readers out there.
Go to Aurinia Pharmaceuticals and read the PR.
There were 13 deaths across the trial: (2) in the high-dose voclosporin arm; (10) in the low-dose voclosporin
arm (10); and (1) in the control arm, with the majority of overall deaths (11/13) occurring in Asia.
All deaths were assessed by the Investigator as being unrelated to study treatment. No dose relationship was observed for the deaths
The only reason why the stock went down is due to lying scumbags who are trying to collect shares at a lower price.
these scumbags title their PR as.
"but deaths send stock down"
or
"Serious side effects"
or more bs on death
and guess what! doing another search of yesterday's PR's they are nowhere to be found.
if anyone reads the PR from Aurinia, they would right away dump a good sum of $ as an investment into it.
The results are great- I also emailed them for further explanation - once I hear back from them, I will report to you guys here.
in the mean time, don't be an idiot - dont give your shares away, seriously, I wish I caught this at 1.7.
Link to PR http://www.auriniapharma.com/dnn/LinkClick.aspx?fileticket=ifNeeSftXPk%3d&tabid=92&mid=738
by EOD this will pass 3.5, the drop was unjust and a result of fear
buy on fear - sell on greed.
According to a recent article -
Summary
Despite Aurinia announcing a successful Phase 2B study for voclosporin meeting its primary endpoints, AUPH's share priced plunged 55% because 13 patients in the study died.
The Phase 2B investigators had concluded that the 13 deaths were unrelated to voclosporin.
Phase 2B results are actually very positive. Aurinia plans to file for Breakthrough Therapy Designation for voclosporin in Q4 with the FDA;
55% share price today was unjustified. This may be a great opportunity to accumulate AUPH shares.
I was thrilled this morning to read Aurinia Pharmaceuticals (NASDAQ: AUPH) press release that its 265 patient Phase 2b clinical trial assessing its lead product candidate voclosporin met its primary efficacy endpoint treating patients with active lupus nephritis (Pending:LN), after 24 weeks of treatment. (Press release.) The Phase 2b trial continues on to week 48. The company held a conference call at 8 a.m. (EST) Monday morning to present the Phase 2b 24 week findings and answer questions. It was all very positive.
During the conference call, Aurinia was clearly thrilled with the Phase 2B results and confirmed that it would be seeking Breakthrough Therapy Designation with the FDA in Q4. The webcast can be accessed on the company's web site for 45 days. My broker sent me an early morning email advising me that AUPH's share price was up about 20% pre-market.
I was therefore more than a little shocked after the market opened when AUPH's share price plunged by about 55% today, trading more than 11 million shares. At first I couldn't figure out what had happened as it appeared the Phase 2b results were so positive. Later in the morning I read that there were concerns that the 13 patients who died during the study had died because of being treated by voclosporin.
Aurinia had explained both in today's press release and the conference call held this morning that all of the 13 patient deaths, while unfortunate, had been investigated thoroughly and none of the 13 deaths were related to voclosporin.
The company's explanation seemed reasonable to me. Before being used by Aurinia in the treatment of LN, voclosporin had been used more than 2,000 times to treat other indications including the prevention of rejection in kidney transplants. It had a very good and well known safety profile already.
As well, if the FDA thought that voclosporin was responsible or could be responsible for any of these 13 patient deaths, you can be sure this study would have been stopped. In fact the study is still continuing to the 48 week mark.
For more information about Aurinia's voclosporin, see my previous articles written about Aurinia published on SA on May 23, 2016 , July 5, 2016 and August 10, 2016.
LN patients are a very sick group of people. I don't believe that the number of deaths in the Phase 2b group of LN patients is unexpected in a group this size, particularly with the large group of LN patients in Asia.
In earlier studies treating LN using current standard of care treatments, similar mortality rates have been seen. The largest LN study conducted to date was in 2008 with the results published in 2009. (See Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis, cited at J. Am. Soc Nephrol 20: 1103-1112, 2009), referred to as the ALMs study. The ALMs study involved 370 LN patients comparing the effectiveness and safety profile of mycophenolate mofetil (MMF) and intravenous cyclophosphamide (NYSE:IVC) in treating LN. While this 2008 ALMs study did not show any significant response rate between the 2 treatments, there were 14 deaths observed in the 2008 ALMs study (9 deaths in the MMF group of which 7 were due to infection and none due to SLE and 5 deaths in the IVF group). In the MMF group, there were 2 deaths in Latin America and 7 in Asia. These are not dissimilar mortality rate figures from the current AUPH Phase 2b study in which there were 13 deaths (11/13 deaths in patients being treated in Asia).
I called Aurinia's COO Michael Martin this morning. He told me he had been celebrating the Phase 2B results this weekend (including a celebratory dinner last night) and was completely shocked at Monday's negative market reaction. Like me he thought the share price would increase significantly in response to the Phase 2b results.
I also called Sandra Raymond, CEO of the Lupus Foundation of America ("LFA"). Sandra has been CEO of LFA for 15 years and was thrilled with Aurinia's Phase 2B trial results. Neither she nor her organization have any business relationship with Aurinia. The Lupus Foundation of America had put out a press release, which states in part:
"The results of this trial are welcomed and exciting news for people with lupus and their doctors who are eager to have more tolerable and effective treatment options. Lupus-related kidney disease is one of the most serious and potentially life threatening complications of lupus, affecting up to 60 percent of people with this autoimmune disease.
"This trial of voclosporin is the first trial of a potential treatment for active lupus nephritis to reach its primary endpoints, offering hope to individuals with lupus that an improved quality of life can soon be achieved. We are excited for the potential that the data from this study represents and we are eager to learn more details of additional analysis as they become available.
"We look forward to the timely commencement of a Phase III trial; and should the findings confirm this study, the addition of this regimen into the arsenal of treatments available to people who have waited far too long for medicines that improve the quality of their lives."
Sandra Raymond told me that she was aware of the 13 deaths in the Phase 2b trial and reminded me of the 14 death of LN patients in the well known 2008 ALMs study. She believed the market didn't understand how serious and potentially deadly LN can be. She was particularly thrilled with the Phase 2B results which showed that voclosporin was effective while taking very low dose levels of steroids. She told me of examples of young women suffering from LN currently who are ending up having hip and knee replacements in their 20s because of current high steroid treatments which can cause major bone and hair loss. She was surprised to hear that investors were treating AUPH's trial results negatively today instead of celebrating the Phase 2b results.
As well, while I have not seen reports from all of the analysts that cover AUPH following Monday's announcement and conference call, I did read Canaccord's report (written today by John Newman, Ph.D., analyst). In the report Canaccord is maintaining its $10 price target on AUPH and expects AUPH to begin a Phase 3 trial in early 2017 with the caveat that he believes the Phase 3 study will be carefully designed with regard to safety.
In short, there is no evidence that voclosporin caused any of the 13 deaths during the Phase 2b study. The independent investigators concluded that all 13 deaths were unrelated to voclosporin. The number of deaths in the Phase 2b study is not dissimilar to the 14 deaths in LN patients in the 2008 ALMs study.
The Phase 2b trial results were really very positive and should be cause for celebration by LN patients, as well AUPH's management and investors.
In my view, AUPH's 55% share price drop today was totally unjustified. The evidence remains that voclosporin may become the new standard of care in treating LN. This may be a great time to accumulate AUPH shares.